FY2027 EPS Estimates for CG Oncology Increased by Analyst

CG Oncology, Inc. (NASDAQ:CGON) – Research analysts at HC Wainwright lifted their FY2027 earnings estimates for CG Oncology in a research report issued on Tuesday, April 7th. HC Wainwright analyst A. Maldonado now forecasts that the company will post earnings of ($1.84) per share for the year, up from their prior forecast of ($1.90). HC Wainwright currently has a “Buy” rating and a $100.00 target price on the stock. The consensus estimate for CG Oncology’s current full-year earnings is ($1.31) per share. HC Wainwright also issued estimates for CG Oncology’s FY2028 earnings at $0.06 EPS.

CG Oncology (NASDAQ:CGON) last announced its quarterly earnings data on Friday, February 27th. The company reported ($0.51) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.61) by $0.10. The company had revenue of $2.32 million for the quarter.

A number of other brokerages have also weighed in on CGON. Royal Bank Of Canada boosted their price objective on shares of CG Oncology from $61.00 to $73.00 and gave the company an “outperform” rating in a report on Wednesday, January 21st. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of CG Oncology in a report on Wednesday, January 21st. The Goldman Sachs Group reaffirmed a “buy” rating and issued a $82.00 price target on shares of CG Oncology in a report on Monday, January 12th. Wall Street Zen lowered shares of CG Oncology from a “hold” rating to a “sell” rating in a report on Saturday, March 28th. Finally, Truist Financial upped their price target on shares of CG Oncology from $66.00 to $75.00 and gave the company a “buy” rating in a report on Tuesday, February 10th. Eleven equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $70.67.

CG Oncology Price Performance

Shares of CGON opened at $68.87 on Thursday. The firm has a market capitalization of $5.81 billion, a PE ratio of -33.27 and a beta of 0.70. CG Oncology has a 1-year low of $14.80 and a 1-year high of $71.90. The company’s fifty day moving average price is $60.03 and its 200-day moving average price is $49.02.

Insider Buying and Selling at CG Oncology

In other CG Oncology news, Director James Mulay sold 11,145 shares of the company’s stock in a transaction dated Friday, January 9th. The shares were sold at an average price of $52.47, for a total value of $584,778.15. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 7.40% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the company. Candriam S.C.A. raised its position in shares of CG Oncology by 35.9% in the third quarter. Candriam S.C.A. now owns 1,037,892 shares of the company’s stock worth $41,806,000 after acquiring an additional 274,312 shares during the period. JPMorgan Chase & Co. raised its position in shares of CG Oncology by 321.3% in the third quarter. JPMorgan Chase & Co. now owns 227,879 shares of the company’s stock worth $9,179,000 after acquiring an additional 173,785 shares during the period. Vanguard Group Inc. raised its position in shares of CG Oncology by 11.4% during the 3rd quarter. Vanguard Group Inc. now owns 6,577,281 shares of the company’s stock worth $264,933,000 after purchasing an additional 670,770 shares during the last quarter. Voya Investment Management LLC raised its position in shares of CG Oncology by 217.6% during the 3rd quarter. Voya Investment Management LLC now owns 47,986 shares of the company’s stock worth $1,933,000 after purchasing an additional 32,877 shares during the last quarter. Finally, Mangrove Partners IM LLC raised its position in shares of CG Oncology by 21.0% during the 3rd quarter. Mangrove Partners IM LLC now owns 671,692 shares of the company’s stock worth $27,056,000 after purchasing an additional 116,575 shares during the last quarter. Institutional investors and hedge funds own 26.56% of the company’s stock.

About CG Oncology

CG Oncology, Inc (NASDAQ: CGON) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibody-based immunotherapies for the treatment of solid tumor cancers. The company leverages a platform-driven approach to identify and optimize antibody candidates that engage key immune checkpoints and co-stimulatory pathways within the tumor microenvironment. Its pipeline encompasses multiple preclinical programs alongside early-phase clinical trials designed to assess safety, dosing and preliminary anti-tumor activity.

Headquartered in South San Francisco, California, CG Oncology conducts clinical research primarily in the United States, collaborating with leading academic medical centers and contract research organizations to advance its lead candidates.